Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

A recent study suggests that Eli Lilly's new weight-loss medication helped individuals lose significant amounts of ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly stock plunges. To find out what lies ahead for Eli Lilly in this increasingly competitive environment, visit CDS.